HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1

被引:15
|
作者
Quesnel-Vallieres, Mathieu [1 ,4 ]
Lemay, Mireille [2 ,5 ]
Lapointe, Normand [2 ,5 ]
Martin, Steven R. [3 ,5 ]
Soudeyns, Hugo [1 ,4 ,5 ]
机构
[1] CHU St Justine, Ctr Rech, Unite Immunopathol Virale, Montreal, PQ H3T 1C5, Canada
[2] CHU St Justine, Ctr Rech, Ctr Maternal & Infantile SIDA, Montreal, PQ H3T 1C5, Canada
[3] CHU St Justine, Ctr Rech, Serv Gastroenterol & Nutr, Montreal, PQ H3T 1C5, Canada
[4] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada
[5] Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ H3C 3J7, Canada
关键词
Hepatitis C virus; Coinfection; Pediatrics; Mother-to-child transmission; Interferon; Ribavirin;
D O I
10.1016/j.jcv.2008.06.019
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Two children who acquired hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infection by mother-to-child transmission were monitored during interferon alfa-2b and ribavirin treatment. In Patient C1, CD4(+) T cell counts were within normal range and HIV-1 viral load was undetectable. HCV viral load declined slightly following treatment initiation while novel variants rapidly emerged, indicative of quasispecies diversification. In Patient C2, CD4(+) T cell counts were low and HIV-1 replication was not fully controlled by antiretroviral therapy. HCV viral load rose during treatment and a striking conservation of the variant spectrum was observed. In both cases, there was no decline in quasispecies complexity following treatment initiation and sustained virological response was not achieved. These results suggest that reduction in quasispecies complexity, which is observed in adult responders following interferon treatment, may be mechanistically unrelated with evolution of the variant profile and/or selective pressure exerted on HCV. (C) 2008 Elsevier B.V. All rights reserved
引用
收藏
页码:236 / 240
页数:5
相关论文
共 50 条
  • [11] Open-label study of the safety and efficacy of interferon alfa-2b plus ribavirin for the treatment of HCV infection in HIV patients.
    Li, JJ
    Sanchez, N
    Monteiro, C
    Cubbedge, L
    Lambiase, LR
    HEPATOLOGY, 2001, 34 (04) : 588A - 588A
  • [12] Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan
    Aziz, Hafsa
    Gil, Muzaffar Latif
    Waheed, Yasir
    Adeeb, Uzama
    Raza, Abida
    Bilal, Iram
    Athar, Muhammad Amin
    INFECTION GENETICS AND EVOLUTION, 2011, 11 (03) : 640 - 645
  • [13] Early HCV-RNA clearance in HIV/HCV-coinfected patients treated with pegylated interferon alfa-2a plus ribavirin
    Camino, N
    Nuñez, M
    Romero, M
    Barreiro, P
    Ocampo, A
    Miralles, C
    Martín-Carbonero, L
    Fernández, A
    García-Samaniego, J
    Soriano, V
    HEPATOLOGY, 2004, 40 (04) : 402A - 403A
  • [14] Peg-interferon alfa-2b and ribavirin in treatment naive African American patients infected with HCV genotype 1.
    Stein, DF
    McKenzie, SD
    HEPATOLOGY, 2003, 38 (04) : 642A - 642A
  • [15] Conventional Interferon Alfa-2b and Ribavirin for 12 Versus 24 Weeks in HCV Genotype 2 or 3
    Farooqi, Javed Iqbal
    Farooqi, Rukhsana Javed
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2008, 18 (10): : 620 - 624
  • [16] SHORT DURATION THERAPY OF PEGYLATED INTERFERON ALFA-2B PLUS RIBAVIRIN FOR HCV GENOTYPE 2 PATIENTS
    Katano, Yoshiaki
    Ishigami, Mosatashi
    Nakano, Isao
    Hayashi, Kazuhiko
    Honda, Takashi
    Goto, Hidemi
    HEPATOLOGY, 2008, 48 (04) : 1146A - 1147A
  • [17] Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients
    Araujo, E. S. A.
    Dahari, H.
    Neumann, A. U.
    de Paula Cavalheiro, N.
    Melo, C. E.
    de Melo, E. S.
    Layden, T. J.
    Cotler, S. J.
    Barone, A. A.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (04) : e52 - e60
  • [18] Safety and efficacy of interferon alfa-2b and ribavirin combination therapy for the treatment of hepatitis C in patients coinfected with HIV.
    Bini, EJ
    Reid, M
    Mannix, RA
    Wu, B
    HEPATOLOGY, 2001, 34 (04) : 335A - 335A
  • [19] Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin
    Petersen, Tess
    Lee, Yu-Jin
    Osinusi, Anu
    Amorosa, Valerianna K.
    Wang, Crystal
    Kang, Minhee
    Matining, Roy
    Zhang, Xiao
    Dou, Diana
    Umbleja, Triin
    Kottilil, Shyam
    Peters, Marion G.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 (07) : 660 - 667
  • [20] Antioxidant treatment does not substantially ameliorate the fall in hemoglobin in HCV patients treated with pegylated interferon alfa-2b and ribavirin
    Bacon, BR
    Freilich, BL
    Siegner, JM
    O'Neill, R
    Kissinger, J
    Hoffmann, JA
    Britton, RS
    Di Bisceglie, AM
    Brass, CA
    GASTROENTEROLOGY, 2004, 126 (04) : A694 - A694